Wells Fargo & Company Raises Pulmonx (NASDAQ:LUNG) Price Target to $16.00 : vimarsana.com

Pulmonx (NASDAQ:LUNG – Free Report) had its target price lifted by Wells Fargo & Company from $15.00 to $16.00 in a research report sent to investors on Thursday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock. Other equities research analysts also recently issued reports about the stock. Piper […]

Related Keywords

Canada , France , French , Piper Sandler , Geoffrey Beran Rose , Wells Fargo Company , Prelude Capital Management , Barclays Plc , Pulmonx Corporation , Capital Partners , Royal Bank , Securities Exchange Commission , Canaccord Genuity Group , Vanguard Group Inc , Pulmonx Company Profile , Free Report , Wells Fargo , Genuity Group , Moderate Buy , Get Free Report , Exchange Commission , Capital Management , Zephyr Endobronchial Valve , Chartis Pulmonary Assessment System , Pulmonx Daily , Pulmonx , Nasdaq Lung , Lung , Medical , Boost Price Target ,